Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS ...

Mitochondrial genome mutations may be linked to ALS, per a study, opening the door for new ways to diagnosing and treating ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

The funding will help support the Ontario Provincial ALS Program to meet the needs of the roughly 1,300 people in Ontario ...

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

Altered activity of ancient viral genes were linked to neurodegenerative diseases including ALS in a recent analysis.

Auttx has received a grant from the ALS Network to advance research on treatments for ALS that could restore normal RNA ...

Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat ...

Long-term treatment with the cell therapy NurOwn was found to significantly extend survival for ALS patients compared with ...

When Dagmar Munn was diagnosed with ALS at the age of 59 in 2010, she tapped into her nearly 30 years of professional health and wellness experience. She not only follows her own advice but also ...

Neurosense Therapeutics will meet with the FDA in early November to discuss plans for a Phase 3 trial to test PrimeC in ALS.